Alnylam Pharmaceuticals | Los Gastos De Explotación



Operating Expenses Cambio Fecha
Acadia Pharmaceuticals USD 232.19M 7.16M 2025-06
Agios Pharmaceuticals USD 139.51M 24.16M 2025-06
Alnylam Pharmaceuticals USD 789.89M 213.78M 2025-06
Amgen USD 6.52B 337M 2025-06
Arrowhead Research USD 193.32M 31.81M 2025-06
BioMarin Pharmaceutical USD 548.52M 27.27M 2025-06
Incyte USD 904.7M 56.97M 2025-06
Ionis Pharmaceuticals USD 312.21M 34.21M 2025-06
Moderna USD 1.04B 113M 2025-06
Neurocrine Biosciences USD 541.9M 7M 2025-06
Novartis USD 10.15B 579M 2024-12
PTC Therapeutics USD 213.73M 7.86M 2025-06
Regeneron Pharmaceuticals USD 2.6B 159.1M 2025-06
Sanofi EUR 6.77B 3.75B 2024-12
Sarepta Therapeutics USD 495.51M 549.73M 2025-06
Takeda JPY 922.12B 206.21B 2025-06
Tectonic Therapeutic USD 13.99M 5.65M 2024-12
Ultragenyx Pharmaceutical USD 274.38M 7.85M 2025-06
Vertex Pharmaceuticals USD 1.81B 71.4M 2025-06
Xencor USD 76.78M 865K 2025-06


Alnylam Pharmaceuticals Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.